SCYX enters its May 6 earnings report carrying two notable developments: a 51% surge in short interest over the past week and a freshly filed S-3 shelf registration for 87 million shares by selling stockholders.
Short interest has climbed sharply — the most striking repositioning in weeks. From roughly 1.4% of free float in mid-April, short interest has doubled to 2.5% of the float. The pace of that build is what stands out: a 51% jump in estimated shares short over seven days, with the total now near 1.45 million shares. The driving catalyst appears to be the May 1 S-3 filing, which announced a prospectus covering 87 million shares by selling stockholders — a dilution overhang that tends to attract fresh short positioning in small-cap pharma names. Borrow costs have climbed alongside, reaching 2.1% from around 0.6% in late March, more than doubling over the past month. That's still far from the distressed end of the borrow market, but the direction of travel is clear. Availability has tightened meaningfully: the lending pool is roughly 26% available relative to current short interest, down from levels above 60% at the start of April — consistent with a market that is adding exposure more quickly than new supply is appearing.
The ORTEX short score of 52, combined with a days-to-cover of 2.6, keeps this away from extreme territory. Options positioning supports that reading. The put/call ratio has been minimal — running at just 0.0003 for most of the past two weeks — well below even its modest 20-day average of 0.001. Options traders are not piling into downside protection despite the shelf filing and short rebuild, which makes the short-interest signal the dominant positioning story rather than a consensus bearish setup.
The Street has not moved on the stock in recent weeks — no analyst rating changes are on record in the current data. The mean price target of $4.19 sits well above the current price of $0.99, implying substantial upside on paper. However, with no recent analyst activity and a stock trading below $1 against a multi-dollar target, that gap likely reflects stale coverage rather than an actionable call. The EPS surprise factor score of 88 is a notable outlier — SCYX ranks in the top 12% of the universe on its history of beating estimates, which matters heading into a print. Factor positioning otherwise looks thin: short-score rank sits in the 32nd percentile and utilization rank at just the 10th.
Insider activity adds a quiet layer of conviction. CEO David Angulo bought approximately 109,000 shares on April 1 at $0.92, spending roughly $100,000 — his fourth open-market purchase since early 2025. Those purchases have come at progressively lower prices, averaging around $0.95 across the cluster. The aggregate sum is modest, but the pattern of a chief executive repeatedly buying near or below $1 is the kind of signal institutional holders tend to notice. Squadron Capital Management and Great Point Partners each hold roughly 9.5% of shares outstanding, with Squadron reporting a fresh full position as of March 31 — they were not previously on the register, making that a meaningful new entry.
Earnings are due after the close on May 6. The most recent comparable event — a March 4 announcement — produced a 5.4% one-day gain and an 18.6% five-day move. The prior November 2025 print delivered a modest decline on the day but a 16.8% five-day recovery. The pattern suggests the stock has historically found buyers in the days following a print rather than on the announcement itself. The shelf registration overhang and the short rebuild mean the week of May 6 will be watched closely — less for the headline earnings number and more for any guidance on the commercial trajectory of ibrexafungerp and how management frames the dilution question raised by the new S-3.
See the live data behind this article on ORTEX.
Open SCYX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
